CDKN2B and cancer: Rs2157719 is also intronic to the non-coding RNA, CDKN2B antisense RNA 1 (CDKN2B-AS1), also known as ANRIL (Figure 3E), which is linked to the progression of diabetic nephropathy, one of the most common T2D complications [57]; however, the prominence of CDKN2B-AS1 in the literature to date is mostly due to its role in cancer, where it can enhance cell proliferation, cell cycle progression, and inhibit apoptosis and senescence.